Selective Neural Nitric Oxide Synthase Inhibitors

Research output: Patent


Novel Peptide Compounds with Selective Inhibition of Neuronal Nitric Oxide Synthase NU2001-036 Inventors Jung-Mi Hah Richard Silverman* Short Description Synthesis of a series of compounds with selective inhibition of neuronal nitric oxide synthase (nNOS) Abstract Northwestern researchers have isolated and identified a series of compounds that have significant implications in the treatment of neurological diseases. The family of NOS enzymes, of which there are three principal isoforms, biosynthesize an important biological second messenger called nitric oxide. While inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are crucial for maintaining body function, the activity of neuronal nitric oxide synthase (nNOS) has become a desired target for control as its overexpression has been implicated in various neurological diseases and neuronal damage. The inhibitory peptides described here demonstrate very high selectivity for inhibition of neuronal nitric oxide synthase over inducible nitric oxide synthase (iNOS) and/or endothelial nitric oxide synthase (eNOS). The novel compounds provide promising solutions for the long-term management of neurological diseased states associated with excess nNOS formation. Applications Therapeutics for neurological disorders: Stroke, Schizophrenia, Migraine Headaches, Cerebral Ischemia, Long-Term Depression, Parkinson's disease and Alzheimer's disease Advantages Selective modulation of nitric oxide synthesis Long-term management of neurological disorders IP Status Issued U.S. Patent No. 6,803,486 Issued U.S. Patent No. 6,274,557 Issued U.S. Patent No. 7,470,815 Contact Information Allan Nader, PhD Invention Manager (p) (847) 491-4456 (e) [email protected]
Original languageEnglish
Patent number6803486
StatePublished - Oct 12 2004


Dive into the research topics of 'Selective Neural Nitric Oxide Synthase Inhibitors'. Together they form a unique fingerprint.

Cite this